Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Cash & Equivalents (2018 - 2025)

Health Catalyst's Cash & Equivalents history spans 8 years, with the latest figure at $50.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 79.65% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $50.8 million, down 79.65%, while the annual FY2025 figure was $50.8 million, 79.65% down from the prior year.
  • Cash & Equivalents reached $50.8 million in Q4 2025 per HCAT's latest filing, up from $40.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $342.0 million in Q1 2025 to a low of $40.3 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $166.9 million, with a median of $155.2 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 245.71% in 2024, then crashed 87.72% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $193.2 million in 2021, then plummeted by 39.81% to $116.3 million in 2022, then fell by 8.63% to $106.3 million in 2023, then surged by 134.9% to $249.6 million in 2024, then tumbled by 79.65% to $50.8 million in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Cash & Equivalents are $50.8 million (Q4 2025), $40.3 million (Q3 2025), and $50.7 million (Q2 2025).